Sarepta Therapeutics Inc (SRPT) Unusual Options Activity Today

Checking SRPT unusual options activity helps you spot when traders are making outsized bets on Sarepta Therapeutics Inc before the broader market catches on. Sarepta Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor SRPT unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching SRPT unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking SRPT unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and SRPT unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program.

It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and SRPT unusual options activity is often where that footprint shows up first. Our scanner tracks Sarepta Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at SRPT unusual options volume on the call side or chasing put sweeps, Sarepta Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.